These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 27412392)

  • 1. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA mismatch repair in cancer.
    Baretti M; Le DT
    Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
    Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
    Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PD-1 blockade in tumors with MMR deficiency.
    Lee V; Le DT
    Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
    [No Abstract]   [Full Text] [Related]  

  • 7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
    Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
    Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Tumor Response to PD-1 Blockade.
    Ding L; Chen F
    N Engl J Med; 2019 Aug; 381(5):477-479. PubMed ID: 31365807
    [No Abstract]   [Full Text] [Related]  

  • 10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
    Hirsch D; Gaiser T; Merx K; Weingaertner S; Forster M; Hendricks A; Woenckhaus M; Schubert T; Hofheinz RD; Gencer D
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):263-273. PubMed ID: 32776177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge.
    Naboush A; Roman CA; Shapira I
    J Investig Med; 2017 Apr; 65(4):754-758. PubMed ID: 28104820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.
    Mishima S; Taniguchi H; Akagi K; Baba E; Fujiwara Y; Hirasawa A; Ikeda M; Maeda O; Muro K; Nishihara H; Nishiyama H; Takano T; Tsuchihara K; Yatabe Y; Kodera Y; Yoshino T
    Int J Clin Oncol; 2020 Feb; 25(2):217-239. PubMed ID: 31286289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
    Fernández A
    Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.
    Chen JA; Esteghamat N; Kim EJ; Garcia G; Gong J; Fakih MG; Bold RJ; Cho MT
    J Natl Compr Canc Netw; 2019 Sep; 17(9):1026-1030. PubMed ID: 31487676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of immunohistochemical loss of mismatch repair protein in double primary cancers of the colorectum and stomach in Japan.
    Hayashi T; Arai M; Ueno M; Kinoshita H; Tada Y; Koizumi K; Miki Y; Yamaguchi T; Kato Y; Utsunomiya J; Muto T; Sugihara K
    Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S23-9. PubMed ID: 17106811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
    N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair deficiency is implicated in carcinoma arising from ovarian teratoma.
    Cheung AH; Chow C; Yu MY; Law WW; Law PP; Choi PC; Kang W; To KF
    Pathology; 2019 Jan; 51(1):67-73. PubMed ID: 30502217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.